Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of VCT220 in Subjects with Hepatic Impairment
NCT06938529Phase 1Completed
- Sponsor
- Vincentage Pharma Co., Ltd.
- Start
- Apr 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of VCT220 in obesity and Overweight (3 arms), sponsored by Vincentage Pharma Co., Ltd. Primary endpoints: Peak Plasma Concentration, Area Under the Serum Concentration Curve From Time 0 to the Last Measurable Concentration and 1 more. Started Apr 2025; status: completed.
02
Drugs
VCT220
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT06938529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06938529.